Don M Benson MD, PhD

Don M Benson MD, PhD
Assoc Professor - ClinicalCollege of Medicinebenson.236@osu.edu
A445 Starling Loving Hall 320 W 10th Avenue Columbus Ohio 43210
Phone:614-366-3802Fax: 614-293-7526
  • Innate Immunity

General Research Interest

Natural Killer cell immunotherapy

Research Description

Our laboratory and clinical research programs seek to develop novel treatments for cancer that harness and enhance the immune system’s ability to detect and kill cancer cells.  Natural killer cells, one type of immune cell in the body, are capable of killing cancer cells and much of the research we do focuses on augmenting or recovering the function of these cells to fight cancer.  Our research has been supported by the National Cancer Institute, CLL Global Research Foundation, the American Cancer Society, the American Society of Clinical Oncology, Multiple Myeloma Research Foundation, Multiple Myeloma Opportunities for Research and Education, and the Ohio State University / Nationwide Children’s Hospital Collaborative Research Award.

Transinstitutional Work

We collaborate with members of the blood and marrow transplant program as well as cancer researchers at Nationwide Children’s Hospital (Columbus OH), as well as researchers in Marseille, France, Copenhagen, Denmark, Yavne, Israel, and a number of other sites in the United States, including researchers at the University of Tennesee (Knoxville, TN), MD Anderson Cancer Center (Houston TX), the Mayo Clinic (Rochester MN), and Karmanos Cancer Center (Detroit MI).  Here at Ohio State, we do research with members of the Pharmacology program, molecular genetics and immunology, and pathology.  We have nearly two dozen open clinical trials for patients with cancer and in the laboratory, we are working on over 5 completely novel, promising cancer therapies for future use in the clinic.

Current Publications

  • Larson RARecombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: Results from Cancer and Leukemia Group B 19808.Cancer 120 1010-7 4/1/2014
  • Spurgeon SEIdelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-d, as therapy for previously treated indolent non-Hodgkin lymphoma.Blood 3/10/2014
  • Furman RRIdelalisib, an inhibitor of phosphatidylinositol 3 kinase p110d, for relapsed/refractory chronic lymphocytic leukemia.Blood 3/10/2014
  • Wagner-Johnston NDResults of a phase I study of idelalisib, a PI3Kd inhibitor, in patients with relapsed or refractory mantle cell lymphoma (MCL).Blood 3/10/2014
  • Hofmeister CC, Poi M, Bowers MA, Zhao W, Phelps MA, Benson DM, Kraut EH, Farag S, Efebera YA, Sexton J, Lin TS, Grever M, Byrd JCA phase I trial of flavopiridol in relapsed multiple myeloma.Cancer Chemother Pharmacol 73 249-57 2/1/2014
  • Caligiuri MACancer Immunology at the Crossroads: Killer immunoglobulin-like receptors and tumor immunity.Cancer Immunol Res 2 99-104 2/1/2014
  • Collins SM, Bakan CE, Swartzel GD, Hofmeister CC, Efebera YA, Kwon H, Starling GC, Ciarlariello D, Bhaskar S, Briercheck EL, Hughes T, Yu J, Rice A, Benson DM JrElotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC.Cancer Immunol Immunother 62 1841-9 12/1/2013
  • Yasmeen R, Meyers JM, Alvarez CE, Thomas JL, Bonnegarde-Bernard A, Alder H, Papenfuss TL, Benson DM Jr, Boyaka PN, Ziouzenkova OAldehyde dehydrogenase-1a1 induces oncogene suppressor genes in B cell populations.Biochim Biophys Acta 1833 3218-27 12/1/2013
  • Harshman SW, Canella A, Ciarlariello PD, Rocci A, Agarwal K, Smith EM, Talabere T, Efebera YA, Hofmeister CC, Benson DM Jr, Paulaitis ME, Freitas MA, Pichiorri FCharacterization of multiple myeloma vesicles by label-free relative quantitation.Proteomics 13(20) 3013-29 10/1/2013
  • Chu J, Deng Y, Benson DM Jr, He S, Hughes T, Zhang J, Peng Y, Mao H, Yi L, Ghoshal K, He X, Devine SM, Zhang X, Caligiuri MA, Hofmeister CC, Yu JCS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma.Leukemia in press 9/26/2013
  • Cohen JB, Hall NC, Ruppert AS, Jones JA, Porcu P, Baiocchi R, Christian BA, Penza S, Benson DM Jr, Flynn J, Andritsos LA, Devine SM, Blum KAAssociation of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma.Bone Marrow Transplant 48(9) 1212-7 9/1/2013
  • Brodsky SVProgressive renal light chain amyloidosis with the absence of detectable free monoclonal light chains after an autologous hematopoietic stem cell transplant for amyloid light chain amyloidosis.Arch Pathol Lab Med 137(9) 1304-8 9/1/2013
  • Jones JA, Rupert AS, Poi M, Phelps MA, Andritsos L, Baiocchi R, Benson DM, Blum KA, Christian B, Flynn J, Penza S, Porcu P, Grever MR, Byrd JCFlavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma.Am J Hematol in press 8/20/2013
  • Dunavin NC, Wei L, Elder P, Phillips GS, Benson DM Jr, Hofmeister CC, Penza S, Greenfield C, Rose KS, Rieser G, Merritt L, Ketcham J, Heerema N, Byrd JC, Devine SM, Efebera YAEarly versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma.Leuk Lymphoma 54(8) 1658-64 8/1/2013
  • He S, Chu J, Wu LC, Mao H, Peng Y, Alvarez-Breckenridge CA, Hughes T, Wei M, Zhang J, Yuan S, Sandhu S, Vasu S, Benson DM Jr, Hofmeister C, He X, Ghoshal K, Devine SM, Caligiuri MA, Yu JMicroRNAs activate natural killer cells through Toll-like receptor signaling.Blood 121(23) 4663-71 6/6/2013
  • Benson DM JrWhen first line therapy for AA-amyloidosis secondary to rheumatoid arthritis fails: a correspondence.Joint Bone Spine 80(2) 229-30 3/1/2013
  • Benson DM JrCan NKT cells extinguish smoldering myeloma?Blood 121(3) 418-20 1/17/2013
  • Olive DA phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission.Blood 120(22) 4317-23 11/22/2012
  • Benson DM Jr, Hofmeister CC, Padmanabhan S, Suvannasankha A, Jagganath S, Abonour R, Bakan C, Andre P, Efebera Y, Tiollier J, Caligiuri MA, Farag SSA phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma.Blood 120(22) 4324-33 11/22/2012
  • Mori S, Crawford BS, Roddy JV, Phillips G, Elder P, Hofmeister CC, Efebera Y, Benson DM JrSerum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents.Hematol Oncol 30(3) 156-62 9/1/2012
  • Godfrey J, Benson DM JrThe role of natural killer cells in immunity against multiple myeloma.Leuk Lymphoma 53(9) 1666-76 9/1/2012
  • Jakubowiak AJ, Benson DM, Bensinger W, Siegel DS, Zimmerman TM, Mohrbacher A, Richardson PG, Afar DE, Singhal AK, Anderson KCPhase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma.J Clin Oncol 30(16) 1960-5 6/1/2012
  • Benson DM Jr, Byrd JCCS1-directed monoclonal antibody therapy for multiple myeloma.J Clin Oncol 30(16) 2013-5 6/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu